Pharmaceutical drug
Pharmaceutical compound
Daunorubicin/cytarabine , sold under the brand name Vyxeos , is a fixed-dose combination medication used for the treatment of acute myeloid leukemia .[ 4] [ 6] It contains the liposomal bound daunorubicin , an anthracycline topoisomerase inhibitor , and cytarabine , a nucleoside metabolic inhibitor.[ 4]
Medical uses
Daunorubicin/cytarabine is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in people aged one year of age and older.[ 4] [ 7] [ 8] [ 9] [ 10]
References
^ a b "Vyxeos APMDS" . Therapeutic Goods Administration (TGA) . 15 June 2022. Archived from the original on 18 June 2022. Retrieved 18 June 2022 .
^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)" . nctr-crs.fda.gov . FDA . Retrieved 22 October 2023 .
^ "Health product highlights 2021: Annexes of products approved in 2021" . Health Canada . 3 August 2022. Retrieved 25 March 2024 .
^ a b c d "Vyxeos (- daunorubicin and cytarabine liposome injection, powder, lyophilized, for suspension" . DailyMed . 13 April 2021. Archived from the original on 29 March 2021. Retrieved 18 June 2022 .
^ "Vyxeos liposomal EPAR" . European Medicines Agency (EMA) . 23 August 2018. Retrieved 25 May 2024 .
^ Molica M, Perrone S, Mazzone C, Cesini L, Canichella M, de Fabritiis P (June 2022). "CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML" . Cancers . 14 (12): 2843. doi :10.3390/cancers14122843 . PMC 9221356 . PMID 35740508 .
^ "Vyxeos (cytarabine/daunorubicin liposomal) dosing, indications, interactions, adverse effects, and more" . Medscape . Archived from the original on 15 August 2017. Retrieved 19 March 2019 .
^ "Vyxeos (cytarabine and daunorubicin) FDA Approval History" . Drugs.com . Archived from the original on 11 April 2019. Retrieved 30 December 2018 .
^ Chen EC, Fathi AT, Brunner AM (2018). "Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML" . OncoTargets and Therapy . 11 : 3425– 3434. doi :10.2147/OTT.S141212 . PMC 6003284 . PMID 29928134 .
^ Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorà A, et al. (October 2020). "CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia". Minerva Medica . 111 (5): 455– 466. doi :10.23736/S0026-4806.20.07017-2 . PMID 32955826 . S2CID 221842680 .